Welcome to Galleon, a leader in the pharmaceutical treatment of breathing-control disorders.
We apply sophisticated pharmacology, medicinal chemistry and drug-discovery tools to identify potential drug treatments for acute and chronic breathing-control conditions associated with surgical anesthesia, drug-induced respiratory depression, pain management and sleep apnea. Our product pipeline reflects recent advances in neurobiology, molecular biology and respiratory medicine which have enabled the development of a unique drug-discovery platform and promising drug candidates that are now undergoing clinical trials.
Galleon Video
Overview 
Corporate Fact Sheet
Galleon Pipeline
Click the chart to
view enlarged version
-
Well-Defined Markets: It is estimated that nearly 30% of the population is at risk for some type of breathing control disorder with complications as severe as stroke, heart attack, or death.
Learn More -
Innovative Products: The Galleon product pipeline includes 2 clinical-stage product candidates with clinical proof-of-concept date beginning in 4Q2011.
Learn More -
Novel Pathways: Galleon has a unique and proven purpose-built, drug discovery platform for the design, discovery and development of breathing control medicines that serve a wide range of therapeutic needs.
Learn More